Skip to main content
. 2004 Sep 13;101(38):13856–13860. doi: 10.1073/pnas.0405972101

Fig. 3.

Fig. 3.

HRG-treated double mutant mdx:utrn–/– mice show no overall improvement. There was no significant difference in body weight (a); average time in therapy before death for age-matched mice (b); and representative muscle pathology as visualized by H&E staining (c) between untreated and HRG-treated double mutant mdx:utrn–/– respectively.